BRAF and neoplasm: Indeed, particularly in ATC cases, in which a definitive cure is unlikely with standard treatments, the molecular signature of the neoplasia could improve the outcome of patients harboring actionable mutations (i.e., BRAF V600E) (24, 39), as well as in a neoadjuvant setting (40).